Generation of tumor-specific cytotoxic T lymphocytesin vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Elizabeth A. Grimm, A Mazumder, H Z Zhang et al. · The Journal of Experimental Medicine · 1982 · 2.2K citations · Full text

Life Sciences, Immunology, Oncology +15

A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes

Steven A. Rosenberg, Paul J. Spiess, René Lafrenière · Science · 1986 · 1.9K citations

Life Sciences, Immunology, Oncology +15

Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response

Eric R. Fearon, Drew M. Pardoll, Toshiuki Itaya et al. · Cell · 1990 · 922 citations

Life Sciences, Immunology, Oncology +17

Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity.

Bernd Gänsbacher, Karen S. Zier, Brian Daniels et al. · The Journal of Experimental Medicine · 1990 · 624 citations · Full text

Medicine, Immunology, Oncology +15

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

Michael T. Lotze, Yvedt L. Matory, Stephen E. Ettinghausen et al. · The Journal of Immunology · 1985 · 614 citations

Life Sciences, Immunology, Pharmacology +9